The importance of acting early to prevent CINV
Experiencing 1 CINV event during the 1st cycle of moderately or highly emetogenic chemotherapy makes CINV in subsequent cycles almost 4 times as likely1
A retrospective study of 10,586 patients receiving prophylactic antiemetics prior to single-day chemotherapy1
- Odds ratio for developing CINV in subsequent cycles in patients receiving highly emetogenic chemotherapy: 3.70 (95% CI, 2.88-4.74), p<0.0001
- Odds ratio for developing CINV in subsequent cycles in patients receiving moderately emetogenic chemotherapy: 3.77 (95% CI, 3.04-4.68), p<0.0001
Chemotherapy-related and patient factors may elevate the risk of CINV1
Emetic risk is influenced by the1:
For multiple-drug regimens, risk is presented based on drug with the highest emetic risk.2
CINV can occur within 24 hours (acute) or from 24 hours to 5 days (delayed) following administration.2,3
Patient risk factors may also impact CINV. These include3,4:
CINV=chemotherapy-induced nausea and vomiting.
References: 1. Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). Curr Med Res Opin. 2011;27:837-845.
2. The NCCN Clinical Practice Guidelines in Oncology®. Antiemesis (Version 2.2015). © 2015 National Comprehensive Cancer Network, Inc. http://www.nccn.org/. Accessed January 8, 2016.
3. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55(2):173-189.
4. National Cancer Institute. Nausea and Vomiting–Health Professional Version (PDQ®). Acute or Delayed Chemotherapy-Induced Nausea and Vomiting (Emesis) Etiology. http://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq#section/_32. Accessed March 8, 2016.